Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1999 Aug;54(8):707–710. doi: 10.1136/thx.54.8.707

Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions

D Thickett 1, L Armstrong 1, A Millar 1
PMCID: PMC1745540  PMID: 10413724

Abstract

BACKGROUND—Investigation and management of pleural effusions is an important clinical problem yet the pathogenesis of pleural fluid accumulation is poorly understood. Vascular endothelial growth factor (VEGF) is a potent inducer of capillary permeability that is produced by both malignant and inflammatory cells. A study was undertaken to determine whether VEGF has a potential pathogenic role in the development of pleural effusions and whether VEGF receptors are present on human pleural mesothelial cells.
METHODS—Normal and inflamed pleura were examined immunohistochemically for the presence of FLT-1 (the fms-like tyrosine kinase receptor of VEGF). VEGF levels were measured by ELISA in 78 consecutive patients presenting with undiagnosed unilateral pleural effusions and the levels were correlated with the aetiology of the effusions.
RESULTS—Immunohistochemical staining of normal and diseased pleura demonstrated the presence of the FLT-1 VEGF receptor on human mesothelial cells. Median VEGF levels were 2500 pg/ml in the malignant group and 305 pg/ml in the non-malignant group (median difference 1397.5 pg/ml (95% CI 851 to 2693), p<0.005). Median VEGF levels varied according to tumour histology. VEGF levels were also significantly raised compared with transudates (median 36.5 pg/ml) in empyema (4651 pg/ml (95% CI 833 to 10 000), p<0.001) and parainfectious effusions (360 pg/ml (95% CI 46 to 597), p<0.005).
CONCLUSIONS—This first report of VEGF receptors on pleural mesothelial cells has indicated a potential mechanism for the biological activity of VEGF on pleural tissue. VEGF levels are raised in the majority of exudative effusions, implying a pathogenic role for this molecule in the development of pleural effusions.



Full Text

The Full Text of this article is available as a PDF (110.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berse B., Brown L. F., Van de Water L., Dvorak H. F., Senger D. R. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell. 1992 Feb;3(2):211–220. doi: 10.1091/mbc.3.2.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Breier G., Albrecht U., Sterrer S., Risau W. Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development. 1992 Feb;114(2):521–532. doi: 10.1242/dev.114.2.521. [DOI] [PubMed] [Google Scholar]
  3. Brem S. Angiogenesis antagonists: current clinical trials. Angiogenesis. 1998;2(1):9–20. doi: 10.1023/a:1009068807898. [DOI] [PubMed] [Google Scholar]
  4. Charan N. B., Baile E. M., Paré P. D. Bronchial vascular congestion and angiogenesis. Eur Respir J. 1997 May;10(5):1173–1180. doi: 10.1183/09031936.97.10051173. [DOI] [PubMed] [Google Scholar]
  5. Dvorak H. F., Brown L. F., Detmar M., Dvorak A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995 May;146(5):1029–1039. [PMC free article] [PubMed] [Google Scholar]
  6. Fava R. A., Olsen N. J., Spencer-Green G., Yeo K. T., Yeo T. K., Berse B., Jackman R. W., Senger D. R., Dvorak H. F., Brown L. F. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med. 1994 Jul 1;180(1):341–346. doi: 10.1084/jem.180.1.341. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gaudry M., Brégerie O., Andrieu V., El Benna J., Pocidalo M. A., Hakim J. Intracellular pool of vascular endothelial growth factor in human neutrophils. Blood. 1997 Nov 15;90(10):4153–4161. [PubMed] [Google Scholar]
  8. Ikubo A., Morisaki T., Katano M., Kitsuki H., Anan K., Uchiyama A., Tanaka M., Torisu M. A possible role of TGF-beta in the formation of malignant effusions. Clin Immunol Immunopathol. 1995 Oct;77(1):27–32. doi: 10.1016/0090-1229(95)90133-7. [DOI] [PubMed] [Google Scholar]
  9. Light R. W., Hamm H. Malignant pleural effusion: would the real cause please stand up? Eur Respir J. 1997 Aug;10(8):1701–1702. doi: 10.1183/09031936.97.10081701. [DOI] [PubMed] [Google Scholar]
  10. Marel M., Zrůstová M., Stasný B., Light R. W. The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia. Chest. 1993 Nov;104(5):1486–1489. doi: 10.1378/chest.104.5.1486. [DOI] [PubMed] [Google Scholar]
  11. Nagy J. A., Masse E. M., Herzberg K. T., Meyers M. S., Yeo K. T., Yeo T. K., Sioussat T. M., Dvorak H. F. Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res. 1995 Jan 15;55(2):360–368. [PubMed] [Google Scholar]
  12. Nehls V., Herrmann R. The configuration of fibrin clots determines capillary morphogenesis and endothelial cell migration. Microvasc Res. 1996 May;51(3):347–364. doi: 10.1006/mvre.1996.0032. [DOI] [PubMed] [Google Scholar]
  13. Taichman N. S., Young S., Cruchley A. T., Taylor P., Paleolog E. Human neutrophils secrete vascular endothelial growth factor. J Leukoc Biol. 1997 Sep;62(3):397–400. doi: 10.1002/jlb.62.3.397. [DOI] [PubMed] [Google Scholar]
  14. Takanami I., Tanaka F., Hashizume T., Kodaira S. Vascular endothelial growth factor and its receptor correlate with angiogenesis and survival in pulmonary adenocarcinoma. Anticancer Res. 1997 Jul-Aug;17(4A):2811–2814. [PubMed] [Google Scholar]
  15. Volm M., Koomägi R., Mattern J. Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Anticancer Res. 1996 Jan-Feb;16(1):213–217. [PubMed] [Google Scholar]
  16. Volm M., Koomägi R., Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer. 1997 Feb 20;74(1):64–68. doi: 10.1002/(sici)1097-0215(19970220)74:1<64::aid-ijc11>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  17. Worrall N. K., Chang K., LeJeune W. S., Misko T. P., Sullivan P. M., Ferguson T. B., Jr, Williamson J. R. TNF-alpha causes reversible in vivo systemic vascular barrier dysfunction via NO-dependent and -independent mechanisms. Am J Physiol. 1997 Dec;273(6 Pt 2):H2565–H2574. doi: 10.1152/ajpheart.1997.273.6.H2565. [DOI] [PubMed] [Google Scholar]
  18. Yeo K. T., Wang H. H., Nagy J. A., Sioussat T. M., Ledbetter S. R., Hoogewerf A. J., Zhou Y., Masse E. M., Senger D. R., Dvorak H. F. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res. 1993 Jun 15;53(12):2912–2918. [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES